Efficacy of Abatacept in Reducing Recurrence Risk in Patients with IgG4-Related Disease: A 48-Week Clinical Evaluation

The primary objective of this study is to demonstrate the efficacy of **abatacept** in reducing the risk of disease recurrence at 48 weeks in patients with **IgG4-related disease**. This objective is clinically relevant as it aims to provide evidence for a targeted treatment option that could potentially improve patient outcomes by minimizing the likelihood of disease flare-ups, thereby enhancing long-term disease management and patient quality of life.

The clinical trial focuses on participants diagnosed with **IgG4-related disease**, aiming to assess the efficacy of abatacept in reducing disease recurrence risk over 48 weeks. The study population includes both male and female subjects who are of legal age and capable of providing informed consent. Participants are either naive to therapy or experiencing a relapse with an IgG4-RD RI greater than 2, and they must meet the 2019 ACR/EULAR Classification Criteria for IgG4-related disease. The age range of participants falls within categories 3 and 4, indicating a broad adult population. The trial does not involve a vulnerable population. Unfortunately, the sponsor has not provided the total number of participants involved in the study. Lifestyle considerations such as diet, physical activity, or habits are not specified in the available data.

The clinical trial is designed to evaluate the efficacy of **abatacept** in reducing the risk of disease recurrence in patients with **IgG4-related disease**. This study is a randomized, double-blind, controlled trial, conducted over a period of approximately 24 months, with an estimated recruitment start date of September 30, 2024, and an estimated end date of August 30, 2026. Participants will be randomly assigned to receive either abatacept or a placebo, administered via subcutaneous use. The trial will include several key phases, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as legal age, ability to provide informed consent, and meeting the 2019 ACR/EULAR Classification Criteria for IgG4-related disease.

Following the screening, eligible participants will undergo a baseline visit where initial assessments and randomization will occur. The primary endpoint of the study is the reduction of disease recurrence in patients treated with abatacept compared to those receiving a placebo. Participants will be involved in the study for a maximum treatment period of 12 months, during which they will attend regular follow-up visits to monitor efficacy and safety outcomes. These visits will include clinical evaluations, laboratory tests, and assessments of disease activity. The end-of-study visit will occur at the conclusion of the treatment period, where final evaluations will be conducted to assess the long-term effects of the treatment.

Participant involvement is expected to last up to 12 months, with conditions for early termination including withdrawal of consent, adverse events, or any other medical reasons deemed necessary by the investigator. The trial is categorized as a Phase 4 study, focusing on post-marketing surveillance to further understand the therapeutic effects and safety profile of abatacept in this patient population. The study aims to provide valuable insights into the management of IgG4-related disease, contributing to the optimization of treatment strategies for affected individuals.

The clinical trial involves the administration of **abatacept**, a biologic agent classified under the ATC code L04AA24. Abatacept is a protein-based therapeutic, specifically categorized as "Protein - Other," and is utilized in the treatment of autoimmune conditions. In this study, abatacept is provided in a pharmaceutical form designated as PHF00231MIG. The medication is administered via the **subcutaneous route**. The dosing regimen for abatacept involves a maximum daily dose of 17.85 mg, with the same amount being the maximum total dose per administration. The treatment period is set for a maximum duration of 12 weeks. The study aims to evaluate the efficacy of abatacept in reducing the risk of disease recurrence in patients with IgG4-Related Disease over a 48-week period.

In addition to the experimental treatment with abatacept, the study may include non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatments, although specific details of these are not provided in the available data. Participant compliance with the dosing schedule will be monitored throughout the trial to ensure adherence to the treatment protocol. The trial does not involve a pediatric formulation of abatacept, and the product is not classified as an orphan drug. The study is designed to provide insights into the co-stimulation of B and T cells as a targeted therapeutic approach for IgG4-Related Disease.

The efficacy of abatacept in the treatment of **IgG4-related disease** will be assessed in this clinical trial. The primary endpoint for evaluating efficacy is the reduction of disease recurrence in patients treated with abatacept compared to those receiving a placebo. The trial aims to demonstrate the efficacy of abatacept in reducing the risk of disease recurrence at 48 weeks. Efficacy assessments will be conducted using validated scales and laboratory tests to measure disease activity and recurrence rates. Data collection will occur at specified timepoints throughout the trial, including the end of the treatment period. The analysis will focus on comparing the outcomes between the abatacept-treated group and the placebo group to determine the treatment's effectiveness in managing IgG4-related disease.